Vytrus Biotech S.A. - Asset Resilience Ratio
Vytrus Biotech S.A. (VYT) has an Asset Resilience Ratio of 0.01% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vytrus Biotech S.A. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Vytrus Biotech S.A.'s Asset Resilience Ratio has changed over time. See what is Vytrus Biotech S.A.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vytrus Biotech S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VYT company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €600.00 | 0.01% |
| Total Liquid Assets | €600.00 | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Vytrus Biotech S.A. maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vytrus Biotech S.A. Industry Peers by Asset Resilience Ratio
Compare Vytrus Biotech S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Vytrus Biotech S.A. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Vytrus Biotech S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | €600.00 ≈ $701.46 |
€11.13 Million ≈ $13.01 Million |
0.00pp |
| 2023-12-31 | 0.01% | €600.00 ≈ $701.46 |
€9.31 Million ≈ $10.89 Million |
0.00pp |
| 2021-12-31 | 0.01% | €520.00 ≈ $607.93 |
€7.18 Million ≈ $8.40 Million |
0.00pp |
| 2020-12-31 | 0.01% | €740.00 ≈ $865.14 |
€6.21 Million ≈ $7.26 Million |
-- |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more